- Full-year 2020 Total Revenues Increased 9% to $1.86 billion
- Company Dose-escalates in PHEarless, a Phase 1/2 Study with BMN 307 Gene Therapy for the Treatment of Phenylketonuria (PKU); the Third Potential Therapeutic Modality in its PKU Franchise
- During the Fourth Quarter, BioMarin Announced Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
- Marketing Applications for Vosoritide to Treat Children with Achondroplasia under Review in Europe and the U.S.; Committee for Medicinal Products for Human Use (CHMP) Opinion Expected in June 2021
- In January 2021, BioMarin Announced Positive Phase 3 Results with Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set; Mean Annualized Bleed Rate was 0.9 in Subset Dosed More than Two Years Ago
you can make a data privacy pledge. you are a company that make product revenues. there are a monster company out there that relies on this free data, that s how they make the money. do you agree some of these companies out there, social media type companies are going to get on board with this? i believe there is hope. why do you think that? first of all, you have to per sway people looking at the long-term. in the short run, a company can make more money bile disregarding the privacy of customers. you got to sustain trust. brad, we are living in an absolute world of short termism. we suffer short termi-termism a. i live in the present.